Lindus Health, a London-based startup, has raised $55 million in Series B funding to innovate the clinical trial process. Founded in 2021 and supported by Peter Thiel, the company aims to address inefficiencies in clinical trials through automation and machine learning. Their platform manages the entire clinical trial lifecycle, enhancing both speed and accuracy. With over 35,000 patients enrolled, Lindus plans to expand its operations from the U.K. to the U.S. and improve integration with third-party tools. This funding will also accelerate their AI applications in real-time data analysis.